Bringing the fundamentals into focus…
Back to Prelude Therapeutics Incorporated
How Prelude Therapeutics Incorporated stacks up
PRLD · against 352 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #217 of 353 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score137 peers with a valuation score of 0–9, including PRLD · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -24.5% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -20.1% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -11.0% vs peer median 0.0%
Metric by metric
Position: dot = PRLD, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | PRLD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 337 reported | -19.3% | -0.4% | 21% | 30% | |
| EBITDA yieldHigher is better · 358 reported | -24.5% | 1.8% | 15% | 50% | |
| Free cash flow yieldHigher is better · 182 reported | -11.0% | -9.2% | 45% | 20% | |
| Book yieldHigher is better · 345 reported | 34.4% | 51.4% | 33% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around PRLD| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 217 | 334M USD | 8 | 49 | |
| 217 | 253M USD | 8 | 15 | |
| 217 | 469M USD | 8 | 45 | |
| 217 | 170M USD | 8 | 35 | |
| 217 | 302M USD | 8 | 42 | |
| 217 | 427M USD | 8 | 7 | |
| 217 | 421M USD | 8 | 52 | |
| 217 | 474M USD | 8 | 25 | |
| 217 | 504M USD | 8 | 24 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score